Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Company Data

Name CHEMOMAB THERAPEUTICSCS LTDRICAN DEPOSITARY SHARES

Company Chemomab Therapeutics Ltd.

Symbol CMMB

Website https://www.chemomab.com

Primary Exchange

NASDAQ

ISIN US16385C1045

Asset Class Depository Receipt

Sector Healthcare

Industry Biotechnology

CEO Adi Mor George

Country Israel

Currency USD

Employees 0,0 T

Address Building 7, 6158002 Tel Aviv

IPO Date 2019-02-12

Stock Splits

Date	Split
26.08.2025	1:4
17.03.2021	1:16

ID Changes

Date	From	To
17.03.2021	ANCN	CMMB

Ticker Symbols

Name	Symbol
Frankfurt	2QV0.F
NASDAQ	CMMB

More Shares

Investors who hold CHEMOMAB THERAPEUTICSCS LTDRICAN DEPOSITARY SHARES also have the following shares in their portfolio:

AMUNDI FUNDS EMERGING MARKETS HARD CURRENCY BOND - I2 EUR (C) ETF

Jiangsu Xiuqiang Glasswork Co., Ltd. Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog